Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... VIENNA , Sept. 17, 2014 ... compelling, quantitative data from a study of the cost ... at the 50 th Annual Meeting of the ... a poster session today, Christian Frois , Ph.D., ... in a series of planned Intarcia-sponsored, retrospective studies to ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Escape Alert, LLC ... pets which will alert owners if their pet has escaped ... from an implanted microchip in the pet’s body. This is ... for pets have been around for many years, they are ... not able to track a pet’s location or alert the owner ...
(Date:9/17/2014)... MA (PRWEB) September 17, 2014 ... Safety (ACRES) , a multi-stakeholder non-profit collaborative building ... efficiency in clinical research, today announced Phase 3 ... , Amir H. Kalali, Vice-President, ... and Arti Bajpai, President, Compliance and Quality Integration ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4
... 17 Initial public offerings for LinkedIn and Dunkin Donuts, takeovers of Mead Johnson Nutrition and Harley-Davidson, and a Cold Stone Creamery sale are among the 10 deals predicted by ... ... ... ...
... , March 17 Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired James ... ... ... ...
... ... Converting to 3D Imaging , ... Thornwood, N.Y. (PRWEB) March 17, 2010 -- Carl Zeiss, a leading provider ... recently announced two exciting online promotions. For a limited time, and only available online, ...
Cached Biology Technology:From Donuts To Hogs - Which Brand Icons Might Be In Play? 2From Donuts To Hogs - Which Brand Icons Might Be In Play? 3From Donuts To Hogs - Which Brand Icons Might Be In Play? 4From Donuts To Hogs - Which Brand Icons Might Be In Play? 5From Donuts To Hogs - Which Brand Icons Might Be In Play? 6From Donuts To Hogs - Which Brand Icons Might Be In Play? 7From Donuts To Hogs - Which Brand Icons Might Be In Play? 8Valeritas Announces Appointment of New CFO 2Valeritas Announces Appointment of New CFO 3Carl Zeiss Offers Online Promotions 2
(Date:9/16/2014)... (17 September, 2014)More than $100 trillion in cumulative ... annual carbon dioxide (CO2)a 40 percent reduction of ... if the world expands public transportation, walking and ... released by the University of California, Davis, and ... , Further, an estimated 1.4 million early ...
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... that spelled doom for the dinosaurs 66 million years ... a much greater extent than their deciduous peers, according ... are published in the journal PLOS Biology . ... of thousands of fossilized leaves of angiosperms ... to reconstruct the ecology of a diverse plant community ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Louis, MO, USA, February 1, 2009 A special ... Journal of the American Dietetic Association presents findings ... Study (SNDA-III), conducted by Mathematica Policy Research, Inc., as ... Sponsored by the Food and Nutrition Service of the ...
... leaders in tropical biology and conservation, William F. Laurance, ... and Thomas E. Lovejoy, research associate at the Institute ... Center for Science, Economics and the Environment, have won ... in Ecology and Conservation Biology, announced on 30 Jan. ...
... LA Huijing Xia, PhD, a postdoctoral research associate ... of Pharmacology at LSU Health Sciences Center New Orleans, ... a recently identified enzyme in the brain plays a ... pressure. The LSUHSC research team showed that Angiotensin-converting enzyme ...
Cached Biology News:Results of the third school nutrition dietary assessment study published 2Results of the third school nutrition dietary assessment study published 3Results of the third school nutrition dietary assessment study published 4Smithsonian scientists receive coveted BBVA Ecology and Conservation Award 2LSUSHC researchers find potential new target for hypertension treatment 2
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... DH-2000 Deuterium Tungsten Halogen Light Source combines ... light sources in a single optical path. The ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... used to reveal two distinct antigens in ... a Zymed polymer double staining detection method ... same human cell or tissue sample with ... using two different primary antibodies from mouse ...
Biology Products: